This Skill Could Change The Way You Trade!
It’s the most valuable strategy for traders to learn, but somehow, most of of them miss out!

Don’t be one of them! Get expert trader Thomas Wood’s guide “Naked Trading Mastery” and see the difference…

Get your free copy here!
Roxanne S. Austin net worth and biography

Roxanne Austin Biography and Net Worth

Director of AbbVie
Roxanne S. Austin is an Independent Director of the Company. Ms. Austin is president of Austin Investment Advisors, a private investment and consulting firm, and chairs the U.S. Mid-market Investment Advisory Committee of EQT Partners. Previously, Ms. Austin also served as the president and chief executive officer of Move Networks, Inc., a provider of Internet television services. Ms. Austin served as president and chief operating officer of DIRECTV, Inc. Ms. Austin also served as executive vice president and chief financial officer of Hughes Electronics Corporation and as a partner of Deloitte & Touche LLP. Ms. Austin is also a director of Abbott Laboratories, Target Corporation, and Teledyne Technologies, Inc. Ms. Austin also served as a director of Telefonaktiebolaget LM Ericsson from 2008 to 2016. Through her extensive management and operating roles, including her financial roles, Ms. Austin contributes significant oversight and leadership experience to the board, including financial expertise and knowledge of financial statements, corporate finance and accounting matters.

What is Roxanne S. Austin's net worth?

The estimated net worth of Roxanne S. Austin is at least $6.55 million as of July 22nd, 2020. Ms. Austin owns 40,043 shares of AbbVie stock worth more than $6,553,437 as of December 3rd. This net worth approximation does not reflect any other investments that Ms. Austin may own. Learn More about Roxanne S. Austin's net worth.

How do I contact Roxanne S. Austin?

The corporate mailing address for Ms. Austin and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Roxanne S. Austin's contact information.

Has Roxanne S. Austin been buying or selling shares of AbbVie?

Roxanne S. Austin has not been actively trading shares of AbbVie during the past quarter. Most recently, Roxanne S. Austin sold 51,844 shares of the business's stock in a transaction on Tuesday, November 2nd. The shares were sold at an average price of $116.38, for a transaction totalling $6,033,604.72. Learn More on Roxanne S. Austin's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 16 times. They sold a total of 997,100 shares worth more than $140,525,236.75. The most recent insider tranaction occured on May, 23rd when Vice Chairman Michael Severino sold 79,801 shares worth more than $12,041,970.90. Insiders at AbbVie own 0.1 % of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 5/23/2022.

Roxanne S. Austin Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/2/2021Sell51,844$116.38$6,033,604.72View SEC Filing Icon  
8/1/2019Buy55,000$65.86$3,622,300.0092,114View SEC Filing Icon  
7/30/2019Buy10,000$66.35$663,500.0062,114View SEC Filing Icon  
6/26/2019Buy11,500$67.50$776,250.0052,114View SEC Filing Icon  
See Full Table

Roxanne S. Austin Buying and Selling Activity at AbbVie

This chart shows Roxanne S Austin's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $163.66
Low: $160.51
High: $163.76

50 Day Range

MA: $148.46
Low: $134.21
High: $163.66

2 Week Range

Now: $163.66
Low: $117.00
High: $175.91


4,252,299 shs

Average Volume

6,597,847 shs

Market Capitalization

$289.43 billion

P/E Ratio


Dividend Yield



This Skill Could Change The Way You Trade!
It’s the most valuable strategy for traders to learn, but somehow, most of of them miss out!

Don’t be one of them! Get expert trader Thomas Wood’s guide “Naked Trading Mastery” and see the difference…

Get your free copy here!